These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 17441915

  • 1. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    Vira MA, Novakovic KR, Pinto PA, Linehan WM.
    BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Editorial comment.
    Rini BI, Shah SN.
    Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract] [Full Text] [Related]

  • 5. Editorial comment.
    Vaishampayan U.
    Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract] [Full Text] [Related]

  • 6. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN, Flaherty KT.
    Clin Cancer Res; 2007 Jul 01; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Renal-cell carcinoma--molecular pathways and therapies.
    Brugarolas J.
    N Engl J Med; 2007 Jan 11; 356(2):185-7. PubMed ID: 17215538
    [No Abstract] [Full Text] [Related]

  • 11. New therapeutic options for renal cell carcinoma.
    Stadler W.
    Clin Adv Hematol Oncol; 2006 Jun 11; 4(6):429-30. PubMed ID: 16981664
    [No Abstract] [Full Text] [Related]

  • 12. Trials probe new agents for kidney cancer.
    Hampton T.
    JAMA; 2006 Jul 12; 296(2):155-7. PubMed ID: 16835411
    [No Abstract] [Full Text] [Related]

  • 13. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y.
    Int J Urol; 2009 May 12; 16(5):444-8. PubMed ID: 19298634
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM.
    Acta Oncol; 2009 May 12; 48(6):927-31. PubMed ID: 19452305
    [No Abstract] [Full Text] [Related]

  • 17. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T.
    Nihon Jinzo Gakkai Shi; 2012 May 12; 54(5):574-80. PubMed ID: 22991835
    [No Abstract] [Full Text] [Related]

  • 18. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ, Rohde D, Peter S.
    Aktuelle Urol; 2010 Jan 12; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Molecular basis of targeted therapy in metastatic renal cancer].
    Moch H.
    Pathologe; 2008 Nov 12; 29 Suppl 2():184-6. PubMed ID: 18751979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.